Table 2.
Author | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Albinet et al., 2010 [32] | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
Byun et al., 2023 [33] | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 7 |
Coelho Junior et al., 2020 [31] | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
Hyodo et al., 2012 [27] | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 5 |
Park et al. [34] | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 8 |
Iuliano et al., 2015 [29] | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 5 |
Kimura et al., 2010 [28] | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 |
Liu Ambrose et al., 2010 [30] | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
Average | 5 * |
1: Inclusion/exclusion criteria; 2: random allocation of participants; 3: concealed allocation; 4: similarity between groups at baseline; 5: participant blinding; 6: therapist blinding; 7: assessor blinding; 8: fewer than 15% dropouts; 9: intention-to-treat analysis; 10: between-group statistical comparisons; 11: point measures and variability data. * Item 1 was not used to calculate the PEDro score.